deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03769168

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis

Sponsor: Novartis Pharmaceuticals

Interventions Secukinumab
Updated 29 times since 2019 Last updated: Oct 8, 2025 Started: Jun 7, 2019 Primary completion: Nov 7, 2024 Completion: Nov 7, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 29 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jun 2025 · 6 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

29 versions recorded
  1. Nov 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  3. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE3

  4. Dec 2024 — Jun 2025 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  5. Nov 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

Show 24 earlier versions
  1. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  6. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

  9. Dec 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

  10. Oct 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  12. Sep 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  13. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  14. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  15. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  16. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE3

  17. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  18. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  19. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  20. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  21. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  22. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  23. Feb 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE3

  24. Jan 2019 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .